secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-007042
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics reports positive proof-of-concept study results in Frontotemporal Dementia
--------------------------------------------------------------------------------

- 9-patient open-label study of low-dose IL-2 + CTLA4-Ig showed no serious adverse events over 22 weeks.
- Treg suppressive function and percentage significantly increased from week 2 through week 22.
- MOCA scores stable (baseline 13.5, week 22: 14) and CDR-FTLD stable (4.8 vs 5.5), indicating no cognitive decline.
- Study led by Houston Methodist Neurological Institute; funded by Peggy and Gary Edwards Endowment Fund.
- Common adverse event was mild injection-site erythema (33.3%); all resolved spontaneously.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526007042/0001193125-26-007042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000119312526007042/d39008d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-007042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer